# Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines.

*biotech · news · 2026-04-29 · Barchart*

## Key points

- Bristol-Myers Squibb forecasts 2026 revenue of $46-47.5 billion, surpassing Wall Street estimates.
- Management expects Eliquis revenue to grow 10%-15% in 2026 despite Medicare price negotiations.
- The company has already achieved $1 billion from its planned $2 billion cost-cutting initiative.
- BMY shares outperformed the S&P 500 and healthcare ETF XLV year-to-date, rising 8%.
- Consensus analyst rating is 'Moderate Buy' with a mean price target implying 7.8% upside.

**Companies:** Bristol-Myers Squibb Company, Pfizer
**Countries:** United States

[Read the full story on Barchart](https://www.barchart.com/story/news/1589866/do-wall-street-analysts-like-bristol-myers-squibb-stock)

---

Canonical: https://newsio.io/n/7f892f04-d3f2-48e9-96aa-d781c5f4b401/bristol-myers-squibb-company-bmy-is-a-global-biopharmaceutical-company-that-disc
Summarized by Newsio from Barchart. https://newsio.io/how-it-works